Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$2.59 +18.3%	$1.46	$0.40 ▼ $2.60	$43.98M	0.19	316,353 shs	809,352 shs
ACTU Actuate Therapeutics	$5.96 +2.4%	$9.14	$5.50 ▼ $11.99	$116.94M	N/A	56,201 shs	966,466 shs
LXEO Lexeo Therapeutics	$4.12 -1.4%	$3.52	$1.45 ▼ $19.50	$136.77M	0.52	538,097 shs	959,826 shs
NMRA Neumora Therapeutics	$0.76 -5.3%	$0.76	$0.61 ▼ $17.19	$122.43M	2.73	1.53 million shs	10.84 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	+40.76%	+85.00%	+201.16%	+253.39%
ACTU Actuate Therapeutics	0.00%	-20.21%	-43.61%	-24.56%	+595,999,900.00%
LXEO Lexeo Therapeutics	0.00%	+5.37%	+43.55%	+0.49%	-71.86%
NMRA Neumora Therapeutics	0.00%	-3.67%	+5.32%	-26.51%	-91.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.324 of 5 stars	0.0	3.0	1.9	0.8	0.0
ACTU Actuate Therapeutics	1.9885 of 5 stars	3.5	0.0	2.6	1.7	0.0
LXEO Lexeo Therapeutics	2.1185 of 5 stars	3.5	1.0	1.6	2.5	0.6
NMRA Neumora Therapeutics	2.5166 of 5 stars	3.1	1.0	2.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
ACTU Actuate Therapeutics	3.00	Buy	$20.50	243.96% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	302.91% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,126.81% Upside

Current Analyst Ratings Breakdown

Latest ABVC, LXEO, NMRA, and ACTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	86.23	N/A	N/A	$0.06 per share	43.17
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
LXEO Lexeo Therapeutics	$650K	210.44	N/A	N/A	$3.53 per share	1.17
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.13	N/A	∞	N/A	-963.46%	-29.62%	-14.08%	8/13/2025 (Estimated)
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-339.73%	N/A
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)

Latest ABVC, LXEO, NMRA, and ACTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
4/30/2025	Q4 2024	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
4/15/2025	Q4 2024	ABVC ABVC BioPharma	N/A	$0.04	N/A	$0.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.22	0.22
ACTU Actuate Therapeutics	N/A	0.46	0.46
LXEO Lexeo Therapeutics	0.01	3.42	3.42
NMRA Neumora Therapeutics	N/A	8.98	8.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ACTU Actuate Therapeutics	N/A
LXEO Lexeo Therapeutics	60.67%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
ACTU Actuate Therapeutics	69.34%
LXEO Lexeo Therapeutics	5.30%
NMRA Neumora Therapeutics	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	14.08 million	Not Optionable
ACTU Actuate Therapeutics	10	19.62 million	6.02 million	N/A
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable

ABVC, LXEO, NMRA, and ACTU Headlines

Recent News About These Companies

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Average PT from Analysts

2 hours ago | americanbankingnews.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Analysts

June 26 at 2:25 AM | marketbeat.com

Neumora Therapeutics Inc News (NMRA) - Investing.com

June 24, 2025 | investing.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by Analysts

June 1, 2025 | marketbeat.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 27, 2025 | globenewswire.com

Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development

May 24, 2025 | uk.investing.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 14, 2025 | prnewswire.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finanznachrichten.de

Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...

May 13, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?

May 11, 2025 | finance.yahoo.com

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 28, 2025 | globenewswire.com

Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 10.34%

April 23, 2025 | aaii.comA

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

April 16, 2025 | investing.com

Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating

April 9, 2025 | tipranks.com

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

April 8, 2025 | accessnewswire.comA

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline

April 7, 2025 | accessnewswire.comA

NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

April 7, 2025 | globenewswire.com

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

April 7, 2025 | globenewswire.com

NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 7, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, LXEO, NMRA, and ACTU Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$2.59 +0.40 (+18.26%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.60 +0.01 (+0.19%)

As of 06/27/2025 07:46 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Actuate Therapeutics NASDAQ:ACTU

$5.96 +0.14 (+2.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.12 +0.16 (+2.68%)

As of 06/27/2025 07:04 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Lexeo Therapeutics NASDAQ:LXEO

$4.12 -0.06 (-1.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.12 +0.00 (+0.12%)

As of 06/27/2025 04:34 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Neumora Therapeutics NASDAQ:NMRA

$0.76 -0.04 (-5.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.80 +0.05 (+6.35%)

As of 06/27/2025 07:46 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time